Magnetotransport properties of a magnetically modulated two-dimensional electron gas with the spin-orbit interaction

We study the electrical transport properties of a two-dimensional electron gas with the Rashba spin-orbit interaction in presence of a constant perpendicular magnetic field $(B_0 \hat z)$ which is weakly modulated by ${\bf B_1} = B_1 \cos (q x) \hat z$, where $B_1 \ll B_0$ and $q = 2 \pi/a$ with $a$ is the modulation period. We obtain the analytical expressions of the diffusive conductivities for spin-up and spin-down electrons. The conductivities for spin-up and spin-down electrons oscillate with different frequencies and produce beating patterns in the amplitude of the Weiss and Shubnikov-de Haas oscillations. We show that the Rashba strength can be determined by analyzing the beating pattern in the Weiss oscillation. We find a simple equation which determines the Rashba spin-orbit interaction strength if the number of Weiss oscillations between any two successive nodes is known from the experiment. We compare our results with the electrically modulated 2DEG with the Rashba interaction. For completeness, we also study the beating pattern formation in the collisional and the Hall conductivities.Comment: 11 pages, 5 figures, re-written with new result

IN VITRO ANTI-INFLAMMATORY AND HEPATOPROTECTIVE ACTIVITY OF TURMESAC®

Objective: In this study, we investigated the hepatoprotective activity of Turmesac® on Human liver cells (HepG2 cell line) and anti-inflammatory effect on Murine macrophages (Raw 264.7 cell line) by flow Cytometry. Methods: Cell viability of HepG2 and Raw 264.7 cells determined by the MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide] assay to identify a non-cytotoxic concentration of Turmesac® for the respective cell lines after 24 h exposure period. Further hepatoprotective effect of Turmesac® was performed in H2O2 treated liver cells using H2DCF-DA staining by flow cytometry. The anti-inflammatory potency of Turmesac® was evaluated in Lipopolysaccharide (LPS 2µg/ml) stimulated Murine Raw 264.7 macrophages by measuring the relative fluorescence intensity of 2 cytokines, Interleukin-8(IL-8) and (Interleukin-12) IL-12 by flow cytometric analysis. Results: Turmesac® concentrations of less than 50μg/ml did not show significant cytotoxicity on both HepG2 and Raw 264.7, cell lines following the treatment period of 24 h and selected 50μg/ml as the optimum concentration for hepatoprotective and anti-inflammatory models. The reactive oxygen species (ROS) study revealed that Turmesac® (50μg/ml) effectively suppressed the H2DCF-DA expression in HepG2 cells. Secondly, Turmesac® significantly suppressed the anti-inflammatory cytokine expressions of IL-8 and IL-12 in LPS pre-stimulated cells categorising as a potentially potent anti-inflammatory drug. The mean fluorescence intensity percentage of IL-8 is control 8.86, LPS 50.49, Turmesac® 19.63 and IL12 is control 10.41, LPS 68.94, and Turmesac® 15.79 respectively. Conclusion: This study highlighted that Turmesac® could be considered as a promising hepatoprotective and anti-inflammatory compound and a therapeutic agent in curing liver-related and inflammation-related diseases

Soil Baiting, Rapid PCR Assay and Quantitative Real TIME PCR to Diagnose Late Blight of Potato in Quarantine Programs

Phytophthora infestans (mont) de Bary is a pathogen of great concern across the globe, and accurate detection is an important component in responding to the outbreaks of potential disease. Although the molecular diagnostic protocol used in regulatory programs has been evaluated but till date methods implying direct comparison has rarely used. In this study, a known area soil samples from potato fields where light blight appear every year (both A1 and A2 mating type) was assayed by soil bait method, PCR assay detection and quantification of the inoculums. Suspected disease symptoms appeared on bait tubers were further confirmed by rapid PCR, inoculums were quantified through Real Time PCR, which confirms presence of P. infestans. These diagnostic methods can be highly correlated with one another. Potato tuber baiting increased the sensitivity of the assay compared with direct extraction of DNA from tuber and soil samples. Our study determines diagnostic sensitivity and specificity of the assays to determine the performance of each method. Overall, molecular techniques based on different types of PCR amplification and Real-time PCR can lead to high throughput, faster and more accurate detection method which can be used in quarantine programmes in potato industry and diagnostic laboratory

Study of evaluation of hepatoprotective potential of lycopene in rat models of paracetamol and antitubercular drugs (isoniazid + rifampicin) induced hepatotoxicity

Background: The exact role of lycopene has not been studied in the past for its hepatoprotective effects. Hence it was decided to explore its anti-oxidant and anti-inflammatory properties in acute and chronic models of drug- induced hepatotoxicity with the aim to evaluate hepatoprotective potential in rat models of paracetamol and antitubercular drugs (isoniazid + rifampicin) induced hepatotoxicity.Methods: The study was carried out in 70 Wistar rats in two phases. In phase I, models of paracetamol and anti-tubercular drugs induced hepatotoxicity were standardized in 22 Wistar rats and in phase II, hepatoprotective potential of lycopene was evaluated in paracetamol and anti-tubercular drugs induced hepatic damage using 48 Wistar rats. The effects of lycopene were compared with silymarin.Results: There was a significant (p <0.05) reduction in serum bilirubin levels with silymarin and lycopene 10mg/kg treated groups signifying protection against hepatic damage, while vehicle control and lycopene 5mg/kg treated groups had high bilirubin values. Similarly, significant (p <0.001) reduction in the levels of serum transaminases were observed with all the treatment groups though more evident in the positive control and lycopene 10mg/kg treated groups.Conclusions: The results of the present study prove that lycopene exerts hepatoprotective effect against paracetamol and anti-tubercular drugs induced hepatic damage in rats. Lycopene needs to be evaluated in other models of hepatotoxicity and further studies are required to delineate its mechanism of action. Lycopene could be a potential hepatoprotective for clinical use in future

Ras hyperactivation versus overexpression : Lessons from Ras dynamics in Candida albicans

We thank Prof. Neta Dean for the CIp10ADH1-Cherry plasmid and Prof. Aaron Mitchell for the BWP17 strain. We gratefully acknowledge Prof. Sudipta Maiti, TIFR, Mumbai, India for providing the data acquisition software. We also appreciate the feedback and discussions with Dr. Rohini Muthuswami, SLS, JNU as well as from the Protein Society group, New Delhi while this study was taking shape. We thank Prof. Alok Bhattacharya for Cytochalasin D. The GC-MS and fluorescence lifetime measurements were carried out at the Advanced Instrumentation Research Facility (AIRF), JNU. Confocal images were recorded either at the central instrumentation facility (CIF), SLS, JNU or at AIRF, JNU. This work was supported by project grants from Department of Biotechnology (DBT, Project grant no. BT/PR20410/BRB/10/1542/2016) and Department of Science and Technology (DST, Project grant no. SB/SO/BB-011/2014), India to S.S.K; and project grants from Department of Information Technology, (DIT, Project grant no. 12(4)/2007-PDD), India to S.S. for FCS setup. In addition, both S.S. and S.S.K. thank DBT-BUILDER for funding support (Project grant no. BT/PR5006/INF/153/2012). S.S.K. also acknowledges funding support from UGC Resource Networking grant to the School of Life Sciences. We thank DST-PURSE and JNU for assistance with funding for publication. G.S.V. and S.C.S. received a fellowship from UGC; V.A.P., B.Y., P.J., N.P., M.F.K. acknowledge CSIR for fellowships. S.L.S. received a fellowship from ICMR. D.T.H. and M.F.K. thank DBT-BUILDER for funding.Peer reviewedPublisher PD

Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review.

BACKGROUND: Pregnant and postpartum women with severe hypertension are at increased risk of stroke and require blood pressure (BP) reduction. Parenteral antihypertensives have been most commonly studied, but oral agents would be ideal for use in busy and resource-constrained settings. OBJECTIVES: To review systematically, the effectiveness of oral antihypertensive agents for treatment of severe pregnancy/postpartum hypertension. SEARCH STRATEGY: A systematic search of MEDLINE, EMBASE and the Cochrane Library was performed. SELECTION CRITERIA: Randomised controlled trials in pregnancy and postpartum with at least one arm consisting of a single oral antihypertensive agent to treat systolic BP ≥ 160 mmHg and/or diastolic BP ≥ 110 mmHg. DATA COLLECTION AND ANALYSIS: Cochrane RevMan 5.1 was used to calculate relative risk (RR) and weighted mean difference by random effects. MAIN RESULTS: We identified 15 randomised controlled trials (915 women) in pregnancy and one postpartum trial. Most trials in pregnancy compared oral/sublingual nifedipine capsules (8-10 mg) with another agent, usually parenteral hydralazine or labetalol. Nifedipine achieved treatment success in most women, similar to hydralazine (84% with nifedipine; relative risk [RR] 1.07, 95% confidence interval [95% CI] 0.98-1.17) or labetalol (100% with nifedipine; RR 1.02, 95% CI 0.95-1.09). Less than 2% of women treated with nifedipine experienced hypotension. There were no differences in adverse maternal or fetal outcomes. Target BP was achieved ~ 50% of the time with oral labetalol (100 mg) or methyldopa (250 mg) (47% labetelol versus 56% methyldopa; RR 0.85 95% CI 0.54-1.33). CONCLUSIONS: Oral nifedipine, and possibly labetalol and methyldopa, are suitable options for treatment of severe hypertension in pregnancy/postpartum

Cognitive Information Processing

Contains reports on seven research projects.National Science Foundation (Grant SED76-81985)Graphic Arts Research Foundation (Grant)Providence Gravure, Inc. (Grant)Associated Press (Grant)National Institutes of Health (Grant 1 RO1 GM22547-01)National Institutes of Health (Grant 1 PO1 AG00354-01)Health Sciences Fund (Grant 76-11